Facet Biotech: Clinical Trials

2 terminated, 1 completed, 1 unknown, 1 withdrawn. 5 Phase 3, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	5	Terminated 2, Completed 1, Unknown 1, Withdrawn 1
Phase 2	3	Terminated 2, Completed 1

Follow Facet Biotech: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study visilizumab - Ulcerative Colitis	Phase 2 / Phase 3	Terminated	Facet Biotech	25	2006-08-01	2012-03-12
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis visilizumab - Ulcerative Colitis	Phase 2 / Phase 3	Terminated	Facet Biotech	127	2006-02-01	2012-03-12
Research Study in Patients With Severe Ulcerative Colitis Visilizumab - Ulcerative Colitis	Phase 2 / Phase 3	Completed	Facet Biotech	20	2002-03-01	2012-03-07
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia lintuzumab, cytarabine, etoposide - Leukemia	Phase 3	Unknown	Facet Biotech		2000-03-01	2013-11-06
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis Visilizumab (HuM291; Nuvion®) - Intravenous Steroid-Refractory Ulcerative Colitis	Phase 3	Withdrawn	Facet Biotech	150		2009-06-25

Conditions studied

Colitis, Ulcerative (4)  ·  Colitis (1)  ·  Colonic Diseases (1)  ·  Digestive System Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Intestinal Diseases (1)  ·  Leukemia (1)  ·  Leukemia, Erythroblastic, Acute (1)  ·  Leukemia, Megakaryoblastic, Acute (1)  ·  Leukemia, Monocytic, Acute (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Myelomonocytic, Acute (1)

Interventions

visilizumab (4)  ·  Cytarabine (1)  ·  Etoposide (1)  ·  Mitoxantrone (1)  ·  lintuzumab (1)

Countries

United States (4)  ·  Belgium (3)  ·  Canada (3)  ·  France (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Australia (2)  ·  Austria (2)  ·  Czechia (2)  ·  Hungary (2)  ·  Israel (2)  ·  Norway (2)  ·  Ukraine (2)  ·  Croatia (1)  ·  Italy (1)

Top investigators

Daniel Levitt, MD, PhD (1)

Results publications

PMID 17920064, PMID 20947884